Enemsa Pharma is a drug discovery company developing high‑impact combination therapies for intractable neurodegenerative and cardiopulmonary diseases—where monotherapies have failed. Inspired by breakthrough successes in oncology and infectious diseases, they target the untapped potential of multi‑mechanism approaches in complex disorders. Their strategy centers on modulating the Integrated Stress Response (ISR), a core cellular survival pathway implicated in many diseases.

Enemsa Pharma’s lead asset, icerguastat, is a clinically validated ISR modulator with Phase 1 completed. By sustaining the protective stress response, icerguastat prevents stress‑induced cell death and serves as a de‑risked backbone for first‑ or best‑in‑class synergistic combinations with approved or standard‑of‑care therapies. Their lead ongoing development program is icerguastat + ambroxol for Parkinson’s disease patients carrying GBA1 mutations, the most common genetic form of PD. This platform unlocks new IP, accelerates partnering, and aims to deliver transformative outcomes for patients with the highest unmet medical needs.